Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus

Clinical Drug Investigation

Volumn 26, Issue 10, 2006, Pages 559-565

  Hung, Yi Jen ^a   Kuo, Shi Wen ^a   Wang, Chao Hung ^b   Chang, Hung Yu ^c   Hsieh, Sheng Hwu ^c   Landen, Harald ^d  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; BIGUANIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SULFONYLUREA;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY WEIGHT; DIABETIC PATIENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NATIONAL HEALTH INSURANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPEN STUDY; PARAMETER; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TAIWAN; VOMITING;

ACARBOSE; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES;

EID: 33748784333     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626100-00002     Document Type: Article

References (27)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections, Diabetes Care 1998; 21: 1414-31
2. Chang CJ, Lu FH, Yang YC, et al. Epidemiologic study of type 2 diabetes in Taiwan. Diabetes Res Clin Pract 2000; 50 Suppl. 2: S49-59
3. Heine RJ, Nijpels G, Mooy JM. New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabet Med 1996; 13 (3 Suppl. 2): S12-4
4. Alberti KGMM. The clinical implications of impaired glucose tolerance. Diabet Med 1996; 13: 927-37
5. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-24
6. The DECODE Study Group. Will new diagnostic criteria for diabetes mellitus change the phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998; 317: 371-5
7. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998; 19: 583-92
8. Duckworth WC. Hyperglycemia and cardiovascular disease. Curr Atheroscler Rep 2001; 3: 383-91
9. The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-404
10. Laube H. Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002; 22: 141-56
11. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-7
12. Yang W, Lin L, Qi J, et al. The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Clin J Endocrinol Metab 2001; 17: 131-6
13. Pan CY, Gao Y, Chen JW, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract 2003; 61: 183-90
14. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 2003; 290: 486-94
15. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-6
16. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204
17. Chan JCN, Chan KWA, Ho LLT, et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Diabetes Care 1998; 21: 1058-61
18. Kado S, Murakami T, Aoki A, et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 41: 49-55
19. Lam KSL, Tiu SC, Tsang MW, et al. Acarbose in NIDDM patients with poor control on conventional oral agents: a 24-week placebo-controlled study. Diabetes Care 1998; 21: 1154-8
20. Lin BJ, Wu HP, Huang HS, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulphonylureas. J Diabetes Complications 2003; 17: 179-85
21. Hwu CM, Ho LT, Fuh MMT, et al. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. Diabetes Res Clin Pract 2003; 60: 111-8
22. Sumual AR, Pandelaki K, Rotty LAW. Acarbose/metformin combination versus metformin alone in Indonesian patients with type 2 diabetes. J ASEAN Fed Endocrine Soc 2003; 21: 24-31
23. Vijan S, Kent DM, Hayward RA. Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus? Diabetologia 2000; 43: 125-30
24. Bayer Healthcare [in Chinese]. Available from: http://www.bayer-pharma. com.tw/product/product_index.asp?class=
25. Neuser D, Benson A, Br̈uckner A, et al. Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Invest 2005; 25: 579-87
26. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108: 15S-22S
27. Qiao Q, Tuomilehto J. Diagnostic criteria of glucose intolerance and mortality. Minerva Med 2001; 92: 113-9